Clinical impact of atrial fibrillation in a nationwide cohort of hypertrophic cardiomyopathy patients

Figures

• 

  Figure 1. Study inclusion flow.

• 

  Figure 2. Impact of atrial fibrillation (AF) on the risk of (A) stroke and (B) mortality in hypertrophic cardiomyopathy patients, stratified by CHA2DS2-VASc scores. Incidence rates (per 100 person-years) of stroke for each CHA2DS2-VASc scores are shown in bar graphs at the bottom with scales on the left. Hazard ratios with 95% confidence intervals representing the risk of stroke for each CHA2DS2-VASc scores are shown in line graphs with scales (base 10 logarithmic) on the right, with a dotted line at 1.

• 

  Figure 3. Performance of the CHA2DS2-VASc score for predicting stroke in hypertrophic cardiomyopathy patients with atrial fibrillation and without anticoagulation. (A) Incidence rates (per 100 person-years) of stroke for each CHA2DS2-VASc scores are shown in bar graphs at the bottom with scales on the left. Hazard ratios with 95% confidence intervals representing the risk of stroke for each CHA2DS2-VASc scores are shown in line graphs with scales (base 10 logarithmic) on the right, with a dotted line at 1. (B) ROC curve for the prediction of stroke at 3 years of follow-up.

• 

  Figure 4. Risk factors for stroke in hypertrophic cardiomyopathy patients with and without AF. †Incidence rate: per 100 person-years. ‡Adjusted for age, comorbidities (hypertension, diabetes mellitus, dyslipidemia, heart failure, prior myocardial infarction, peripheral artery disease, COPD, ESRD), BMI, CrCl, smoking, drinking, exercise, presence of oral anticoagulation. §vs. SBP/DBP <120/80 (reference). ¶Q4 (4th quartile) vs. Q1 (1st quartile; reference). AF, atrial fibrillation; HR, hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; BMI, body mass index; CrCl, creatinine clearance; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyltransferase.